Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: A nested case-control study in UK general practice

European Journal of Heart Failure

Volumn 17, Issue 2, 2015, Pages 205-213

  Michel, Alexander ^a   Martín Pérez, Mar ^b   Ruigómez, Ana ^b   García Rodríguez, Luis A ^b  

^a BAYER PHARMA AG   (Germany)

^b Department of Pharmacoepidemiology   (Spain)

Author keywords

Case control; Heart failure; Hyperkalaemia; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; AMOXICILLIN; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; MACROLIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; POTASSIUM; QUINOLONE DERIVATIVE; SPIRONOLACTONE; TETRACYCLINE DERIVATIVE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; TRIMETHOPRIM; WARFARIN; DIURETIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; FOLLOW UP; GENERAL PRACTICE; HEART FAILURE; HUMAN; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIFESTYLE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; VALVULAR HEART DISEASE; ADOLESCENT; CASE CONTROL STUDY; CHEMICALLY INDUCED; CHILD; INFANT; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIURETICS; GREAT BRITAIN; HEART FAILURE; HUMANS; HYPERKALEMIA; INFANT; MIDDLE AGED; RISK FACTORS; SPIRONOLACTONE; YOUNG ADULT;

EID: 84922855366     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.226     Document Type: Article

References (30)

1. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ 2009; 339: b4114.
2. Desai A. Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit. Circulation 2008; 118: 1609-1611.
3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
5. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
6. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA 2009; 302: 1658-1665.
7. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.
8. de Denus S, Tardif JC, White M, Bourassa MG, Racine N, Levesque S, Ducharme A. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. Am Heart J 2006; 152: 705-712.
9. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 2007; 50: 1959-1966.
10. Hu LJ, Chen YQ, Deng SB, Du JL, She Q. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis. Br J Clin Pharmacol 2013; 75: 1202-1212.
11. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
12. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012; 109: 1510-1513.
13. Heerspink HJ, Gao P, Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol 2014; 21: 299-309.
14. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008; 14: 181-188.
15. Weir MA, Juurlink DN, Gomes T, Mamdani M, Hackam DG, Jain AK, Garg AX. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study. Clin J Am Soc Nephrol 2010; 5: 1544-1551.
16. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009; 169: 1587-1594.
17. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225.
18. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283: 1295-1302.
19. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
20. Hawboldt JMD. Possible metoprolol-induced hyperkalemia. J Pharm Pract 2006; 19: 320-325.
21. Imamura T, Matsuura Y, Nagoshi T, Ishikawa T, Date H, Kita T, Matsuyama A, Matsuo T, Eto T. Hyperkalemia induced by the calcium channel blocker, benidipine. Intern Med 2003; 42: 503-506.
22. Freed MI, Rastegar A, Bia MJ. Effects of calcium channel blockers on potassium homeostasis. Yale J Biol Med. 1991; 64: 177-186.
23. Korgaonkar S, Tilea A, Gillespie BW, Kiser M, Eisele G, Finkelstein F, Kotanko P, Pitt B, Saran R. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 2010; 5: 762-769.
24. Formica RN Jr, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 2006; 21: 1389-1394.
25. Aljadhey H, Tu W, Hansen RA, Blalock S, Brater DC, Murray MD. Risk of hyperkalemia associated with selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf 2010; 19: 1194-1198.
26. Lafrance JP, Miller DR. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. Am J Kidney Dis 2012; 60: 82-89.
27. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 2010; 170: 1045-1049.
28. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 2011; 183: 1851-1858.
29. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-1650.
30. Cryer PK, Kissane JM. Valvular heart disease, hyperkalemia and death. Am J Med 1977; 62: 743-750.